EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Rescue Vedolizumab Therapy for a Rare Case of Complicated Severe Ulcerative Colitis: A Case Report and Literature Review

Shih-Tsung Fu, Kai-Po Chang, Wei-Jhe Hong, Jen-Wei Chou, Yi-Hua Wu iD

Journal of Clinical Medicine · 02.07.2026 · 15 (13) · 5166

DOI: 10.3390/jcm15135166 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.07.2026. Verfasst von Shih-Tsung Fu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with extraintestinal manifestations, including primary sclerosing cholangitis (PSC). Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that rarely coexists with UC or PSC. The concurrent occurrence of UC, PSC, and SLE in a single individual represents a unique diagnostic and therapeutic challenge. Vedolizumab, a gut-selective biologic agent, is effective for managing UC; however, its utility in patients presenting with this triad of conditions has not yet been explored. Case summary: A 32-year-old man presented with a 10-year history of recurrent upper abdominal pain, frequently accompanied by high-grade fever, along with recent onset of jaundice, diarrhea, hematochezia, and chronic rashes. Diagnostic evaluation confirmed PSC, SLE, and severe UC. During hospitalization, the patient also developed bacteremia. Initial management of UC with mesalazine and immunosuppressants (azathioprine followed by cyclosporine) resulted in limited clinical improvement. Vedolizumab was subsequently initiated, resulting in marked clinical improvements and near-complete endoscopic remission of UC. PSC and SLE remained clinically stable with ongoing therapies; however, the patient is currently awaiting liver transplantation for PSC.

Conclusions

This case highlights the potential utility of vedolizumab in the treatment of UC in patients with concurrent PSC and SLE.

Schlagwörter

Stichwörter der Autor:innen

autoimmune overlapinflammatory bowel diseaseprimary sclerosing cholangitissystemic lupus erythematosusulcerative colitisvedolizumab

Autor:innen und Institutionen

  • Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan.
  • School of Medicine, College of Medicine, China Medical University, Taichung 404, Taiwan.
  • Department of Pathology, China Medical University Hospital, Taichung 404, Taiwan.
  • Division of Rheumatology and Immunology, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan.

ORCID-Profile: Yi-Hua Wu

Zitieren

APA

Fu, S. T., Chang, K. P., Hong, W. J., Chou, J. W., & Wu, Y. H. (2026). Rescue Vedolizumab Therapy for a Rare Case of Complicated Severe Ulcerative Colitis: A Case Report and Literature Review. Journal of Clinical Medicine, 15(13), 5166. https://doi.org/10.3390/jcm15135166

Vancouver

Fu ST, Chang KP, Hong WJ, Chou JW, Wu YH. Rescue Vedolizumab Therapy for a Rare Case of Complicated Severe Ulcerative Colitis: A Case Report and Literature Review. Journal of Clinical Medicine. 2026;15(13):5166. doi:10.3390/jcm15135166

BibTeX
@article{Fu2026,
  author = {Fu, Shih-Tsung and Chang, Kai-Po and Hong, Wei-Jhe and Chou, Jen-Wei and Wu, Yi-Hua},
  title = {Rescue Vedolizumab Therapy for a Rare Case of Complicated Severe Ulcerative Colitis: A Case Report and Literature Review},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {5166},
  doi = {10.3390/jcm15135166}
}
Kostenlos starten →